Cell and Gene Therapy Manufacturing Market to Reach Valuation of USD 15.4 Billion by 2030 – Growth in the Usage of Advanced Biotechnology and Genetic Engineering Techniques Drive The Market

In terms of revenue, the Global Cell and Gene Therapy Manufacturing Market is expected to reach by 2030, growing at a CAGR of 18.2% from 2023 to 2030.

The growth of the Cell and Gene Therapy Manufacturing market can be attributed to several factors. The increase in the incidence of chronic diseases worldwide is one of the main factors driving this market. The promise for cell and gene treatments to treat and even eradicate diseases like cancer, HIV/AIDS, and genetic disorders is enormous. Technological advances have also made a new generation of effective and efficient medicines possible. Governments and biopharmaceutical companies investing more money in research and development have also aided the market's expansion. The industry for manufacturing cell and gene therapies has also expanded as a result of academic institutions and contract manufacturing companies participating in this sector more and more. Personalized therapies and regenerative medicine are becoming increasingly popular, which has led to a boom in the cell and gene therapies market.

Key Highlights from the Report

. Based on the Therapy Type, the ability of cell therapy to directly target and treat a variety of diseases at the cellular level has made it the market leader in the therapy type segment of theCell and Gene Therapy Manufacturing market. This therapy offers personalized treatments that can be tailored to individual patients through living cells, leading to better clinical outcomes. For instance, CAR-T cell therapy has transformed how some cancers are treated by boosting the patient's immune system to specifically target cancer cells. Cell therapy's dominance in this market has also been furthered by its regenerative abilities, which have shown promising results in ailments like spinal cord injuries and heart diseases.

. Based on Application, due to its capacity to meet rising demand, guarantee standardized quality and safety, and achieve cost effectiveness, commercial manufacturing dominates the application segment of theCell and Gene Therapy Manufacturing market. This trend makes it easier for patients to access these transformative therapies, providing new options for treating a variety of diseases and advancing the field.

. Based on Indication, Cancer undoubtedly dominates the indications segment of theCell and Gene Therapy Manufacturing market. Numerous types of cancer have responded favorably to cell and gene therapies, and great strides have been made in this field in recent years. CAR-T cell therapy is one illustration, which entails altering a patient's own T cells to recognize and eliminate cancer cells. Acute lymphoblastic leukemia and non-Hodgkin lymphoma have both been successfully treated with this ground-breaking therapy. Another illustration is gene therapy for solid tumors, which targets cancer cells and introduces particular genes to stop their growth.

. Based on End-User, Pharmaceutical and Biotechnology Companies dominate the end-user segment in the market for the manufacture of cell and gene therapies. These businesses are essential to creating and marketing cell and gene therapies, providing cutting-edge medical care to patients worldwide. Companies in the pharmaceutical and biotechnology industries are well-suited to take the lead in producing and distributing these therapies due to their extensive resources and experience in drug discovery, clinical research, and regulatory compliance.

. In terms of Region, North America is expected to be the dominating region in

for Cell and Gene Therapy Manufacturing market during the projected period. The region has a strong infrastructure for R&D, which makes it possible for manufacturing processes to be effective. Leading businesses like Pfizer, Novartis, and Bluebird Bio have established advanced manufacturing facilities in the US. Furthermore, the robust regulatory environment in North America encourages innovation and speeds up the launch of new treatments. The region's sophisticated healthcare system and high patient demand for cutting-edge therapies support market expansion. Overall, North America provides a favorable environment for producing cell and gene therapies, accounting for its market dominance. 

Market Dynamics

The need for gene therapy is rising, the usage of regenerative medicines to treat cancer is expanding, and biotechnology developments are all contributing to the rapid growth of the Cell and Gene Therapy Manufacturing Market. Globally, there are also more clinical trials and product approvals for cell and gene therapy, which further supports market expansion.

The market is expanding as a result of an increase in government initiatives, favorable laws, and financial assistance for the development of cell and gene therapies. On the other hand, some of the key barriers preventing market expansion are the high costs and complicated processes involved in manufacturing cell and gene therapies. Additionally, it is anticipated that the lack of experienced workers and the requirement for specialized infrastructure and equipment will restrain market expansion.

In terms of market trends, autologous cell therapy, which uses a patient's own cells to improve therapeutic outcomes, is becoming more popular. Because personalized medicine offers a more accurate and effective form of treatment than conventional medicines, this development is increasing demand for it.

In the near future, the market will provide considerable growth prospects for participants through partnerships and collaborations for R&D, mergers and acquisitions, and the introduction of cutting-edge manufacturing technologies. The manufacturing market for cell and gene therapies is expected to increase rapidly over the next several years as a result of these growth drivers, noticeable trends, restraints, and opportunities.

North America dominated the overall Cell and Gene Therapy Manufacturing market in 2022, North America Cell and Gene Therapy Manufacturing Market is estimated to be the most dominant region during the projected period. Leading biotech firms, large R&D investments, and supportive regulatory frameworks are only a few of the elements that contribute to North America's dominance. Additionally, the expansion of the industry in the area has been aided by growing collaborations between academic institutions, governmental organizations, and private-sector businesses. Additionally, the accessibility of highly qualified labor and cutting-edge manufacturing facilities has been vital in luring significant investors from the worldwide market.

The Global Cell and Gene Therapy Manufacturing Market is Segmented as follows

• Type
  • Cell Therapy
  • Gene Therapy
• Indication
  • Oncology Diseases
  • Inherited Disorders
  • Cardiovascular Diseases
  • Musculoskeletal Disorders
  • Neurological Diseases
  • Other Indications
• Application
  • Clinical Manufacturing
  • Commercial Manufacturing
• End User
  • Pharmaceutical & Biotechnology Companies
  • Contract Manufacturing Organizations (CMOs)
  • Research Institutes & Academic Centers
  • Regulatory Agencies
  • Other End Users
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

A list of the Key Players of the Global Cell and Gene Therapy Manufacturing Market is

Lonza (Switzerland), Bluebird Bio (U.S.), Catalent Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Samsung Biologics (South Korea), Boehringer Ingelheim (Germany), Cellular Therapeutics (China), Hitachi Chemical Co. Ltd. (Japan), Takara Bio Inc. (Japan), Miltenyi Biotec (U.S.), Thermo Fisher Scientific (U.S.), Novartis International AG (Switzerland), Merck KGaA (Germany), Wuxi Advanced Therapies (U.S.), Fujifilm Holdings Corp. (Japan), Charles River Laboratories International Inc. (U.S.), GE Healthcare Life Sciences (U.S.), CGT Catapult (UK), CoJourney Inc. (China), ElevateBio LLC (U.S.), Pfizer Inc. (U.S.), Incyte Corp. (U.S.), AllogeneTherapeutics Inc. (U.S.)

The Global Cell and Gene Therapy Manufacturing Market Scope can be Tabulated below